NASDAQ : ZNTL
Zentalis Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.99 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 188.40M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 185.56M |
| Enterprise Value | 48.64M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 94.67M |
| Shares Outstanding | 94.67M |
| Shares Change (YoY) | -0.23% |
| Shares Change (QoQ) | +1.51% |
| Owned by Insiders (%) | 2.12% |
| Owned by Institutions (%) | 50.58% |
| Float | 74.82M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 156.30 |
| PB Ratio | 0.98 |
| P/TBV Ratio | 1.29 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.82 |
| Quick Ratio | 4.64 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -66.75% |
| Return on Assets (ROA) | -33.15% |
| Return on Invested Capital (ROIC) | -37.81% |
| Return on Capital Employed (ROCE) | -84.63% |
| Weighted Average Cost of Capital (WACC) | 12.39% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.32M |
| Employee Count | 106 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 700,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.94 |
| 52-Week Price Change | +28.11% |
| 50-Day Moving Average | 2.95 |
| 200-Day Moving Average | 3.45 |
| Relative Strength Index (RSI) | 31.06 |
| Average Volume (20 Days) | 1,330,384 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.99M |
| Short Previous Month | 5.96M |
| Short % of Shares Out | 6.32% |
| Short % of Float | 8.00% |
| Short Ratio (days to cover) | 4.40 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -150.39M |
| Pretax Income | -138.85M |
| Net Income | -139.55M |
| EBITDA | -149.77M |
| EBIT | -150.39M |
| Earnings Per Share (EPS) | -$1.96 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 174.61M |
| Total Debt | 37.69M |
| Net Cash | 136.92M |
| Net Cash Per Share | $1.45 |
| Equity (Book Value) | 143.65M |
| Book Value Per Share | 2.00 |
| Working Capital | 143.65M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -128.10M |
| Capital Expenditures | -34,000 |
| Depreciation & Amortization | 621,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -128.13M |
| FCF Per Share | -$1.35 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 0.23% |
| Shareholder Yield | 0.23% |
| Earnings Yield | -99.78% |
| FCF Yield | -69.05% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $7.33 |
| Price Target Difference | 274.13% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |